This website uses cookies to improve your experience.

Cookie policy

Atezolizumab plus bevacizumab versus active surveillance in patients with resected or ablated high-risk hepatocellular carcinoma (IMbrave050): a randomised, open-label, multicentre, phase 3 trial.

Qin S, Chen M, Cheng A-L, Kaseb AO, Kudo M, Lee HC et al, for the IMbrave50 investigators.

Lancet 2023; 402:

In this study that included 668 patients followed for a median of 17.4 months, adjuvant treatment improved recurrence-free survival: hazard ratio 0.72, 95 per cent confidence interval 0.53 to 0.98, P=0.012.

Comment: Among the first to show a benefit from adjuvant treatment with immunotherapy.

Read paper


Part of the charitable activity of the Foundation, BJS Academy is an online educational resource for current and future surgeons.

The Academy is comprised of five distinct sections: Continuing surgical education, Young BJS, Cutting edge, Scientific surgery and Surgical news. Although the majority of this is open access, additional content is available to BJS subscribers and strategic partners.

Discover the Academy
Surgeon Training & Surgeons in Surgery